Spero Therapeutics, Inc. announced that it has entered into a securities purchase agreement with new investor Pfizer Inc. for private placement of 2,362,348 common shares $16.93 per share for gross proceeds of $39,994,551.64 on June 30, 2021. The company has raised funding as part of the Pfizer Breakthrough Growth Initiative. The company received funding from 1 investor pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.36 USD | -0.73% |
|
-3.20% | -7.48% |
May. 15 | Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q1 Revenue $9.3M | MT |
May. 15 | Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.48% | 73.42M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- SPRO Stock
- News Spero Therapeutics, Inc.
- Spero Therapeutics, Inc. announced that it has received $39.994552 million in funding from Pfizer Inc.